- Report
- February 2025
- 200 Pages
Global
From €4229EUR$4,490USD£3,617GBP
- Report
- October 2021
- 54 Pages
Global
From €2355EUR$2,500USD£2,014GBP
- Report
- August 2023
- 104 Pages
Global
From €3500EUR$3,980USD£3,098GBP
- Report
- April 2025
- 50 Pages
Global
From €2496EUR$2,650USD£2,135GBP
Mycophenolic Acid (MPA) is an immunosuppressive drug used to prevent organ rejection in transplant patients. It is a prodrug of mycophenolic acid glucuronide, which is the active form of the drug. MPA works by inhibiting inosine monophosphate dehydrogenase, an enzyme involved in the synthesis of purines, which are essential for the growth and replication of lymphocytes. This reduces the number of lymphocytes in the body, which helps to prevent organ rejection. MPA is available in both oral and intravenous formulations.
MPA is used in combination with other immunosuppressive drugs, such as corticosteroids and calcineurin inhibitors, to reduce the risk of organ rejection. It is also used to treat autoimmune diseases, such as rheumatoid arthritis and lupus.
The MPA market is highly competitive, with several major players. These include Mylan, Teva Pharmaceuticals, Sandoz, and Pfizer. Other companies in the market include Dr. Reddy's Laboratories, Sun Pharmaceuticals, and Lupin Pharmaceuticals. Show Less Read more